Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas.

Transplantation and cellular therapy·2026

Same author

Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.

International journal of laboratory hematology·2026

Same author

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026

Same author

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.

Transplantation and cellular therapy·2026

Same author

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Transplantation and cellular therapy·2026

Same author

CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease.

The New England journal of medicine·2026

Search research articles

Related Experiment Video

Updated: Dec 9, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Advances in chimeric antigen receptor T cells.

Ofrat Beyar-Katz¹, Saar Gill^1,2

¹Center for Cellular Immunotherapies.

Current Opinion in Hematology

|September 14, 2020

Summary

Recent advances in Chimeric Antigen Receptor (CAR) T cell therapy have led to significant clinical milestones. This immunotherapy platform is rapidly evolving, showing promise for improved treatment of hematological malignancies.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Dec 9, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric Antigen Receptor (CAR) T cell therapy has seen major development over the last three years.
Regulatory approvals in the US, Europe, Canada, Australia, and Japan mark significant milestones.
Multiple CAR T cell products targeting the CD19 antigen are now available.

Purpose of the Study:

To review important advances in CAR T cell therapy over the past year.
To focus on available clinical results and outcomes.

Main Methods:

Review of recent clinical data and regulatory approvals for CAR T cell therapies.
Analysis of CAR T cell constructs targeting the CD19 antigen.

Main Results:

FDA approval of Tisagenlecleucel, Axicabtagene Ciloleucel, and Brexucabtagene Autoleucel for various relapsed/refractory hematological malignancies.
CAR T cell therapies have received regulatory approval in multiple countries worldwide.
All approved products target CD19 but differ in costimulatory molecules, with clinical activity and toxicity differences yet to be determined.

Conclusions:

The CAR T cell platform is rapidly evolving.
CAR T cell therapy is expected to further improve therapeutic outcomes for hematological malignancies.